Company

Company

Relevant Interviews, Webinar and Trial Updates posted by CRISPR Medicine News.

Always stay updated with the free CMN Newsletter.

ENSOMA

Company Type: Therapeutics

Main focus: In vivo editing via virus-like particles (VLPs) and adenovirus

Company stage: Pre-clinical

Diseases: Targeting any cell of the haematopoietic system to cure diseases from within

Genome-editing tool: Cas12a ( from Twelve Bio)

Funding stage: Series B

Location: Boston USA

Website: ensoma.com

Pipeline:

Partners:

Ensoma is a pre-clinical-stage company that aims to engineer directly haematopoeitic stem cells, T cells and other immune cell types, in vivo, by delivering a genome editor via their proprietary virus-like-particles (VLPs) platform, which is also known as Engenious.

Your Latest CMN News

CelFi Assay Tracks Indels to Validate CRISPR...

A new CRISPR-based method has been developed to functionally validate hits from pooled knockout screens by measuring shifts in indel profiles that...

Wrapping up CRISPRMED25, and Gearing up for...

CMN Editor-in-chief Karen O’Hanlon Cohrt shares highlights from the second CRISPR Medicine Conference, CRISPRMED25, held last week in Copenhagen.

Light-activated crRNAs enable controlled CRISPR...

A new strategy enables precise spatial and temporal control of CRISPR gene editing using chemically modified, photo-responsive guide RNAs. This...

Gene editing boosts immunotherapy

A new review outlines genetic engineering strategies, including CRISPR, to enhance the therapeutic potential of innate immune cells in cancer...

Quantum-Enhanced CRISPR-Based Epigenome Editing:...

Research presented at Copenhagen's CRISPRMED25 conference unveils a quantum-enhanced epigenome editing approach that harnesses nitrogen-vacancy...

Quantum-Guided Gene Editing in a Life-Saving Bone...

A case study presented at CRISPRMED25 shows how quantum biosensors monitored prime editing to correct a sickle cell mutation in donor bone marrow...

Company: ENSOMA

Search CRISPR Medicine